Skip to content
Triangle logo TriangleGet started
← Melanoma

TREATMENT READING

Melanoma, part 2

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

123 sections
  1. Treatment Option Overview for Melanoma
  2. Excision
  3. Lymph node management
  4. Sentinel lymph node biopsy (SLNB)
  5. Complete lymph node dissection (CLND)
  6. Adjuvant Therapy
  7. Neoadjuvant Therapy
  8. Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease
  9. Immunotherapy
  10. Checkpoint inhibitors
  11. Interleukin-2 (IL-2)
  12. Dual checkpoint inhibition
  13. Signal transduction inhibitors
  14. BRAF inhibitors
  15. Vemurafenib
  16. Dabrafenib
  17. Encorafenib
  18. MEK inhibitors
  19. Trametinib
  20. Cobimetinib
  21. Binimetinib
  22. c-KIT inhibitors
  23. Combination signal transduction inhibitor therapy
  24. Combination signal transduction inhibitor therapy plus anti–PD-L1 therapy
  25. Chemotherapy
  26. Dacarbazine
  27. Temozolomide
  28. Palliative local therapy
  29. Treatment of Stage 0 Melanoma
  30. Treatment Options for Stage 0 Melanoma
  31. Excision
  32. Treatment of Stage IA Melanoma
  33. Treatment Options for Stage IA Melanoma
  34. Excision
  35. Sentinel lymph node biopsy
  36. Treatment of Stage IB Melanoma
  37. Treatment Options for Stage IB Melanoma
  38. Excision
  39. Lymph node management
  40. Treatment of Stage II Melanoma
  41. Treatment Options for Stage II Melanoma
  42. Excision
  43. Lymph node management
  44. Lymphatic mapping and sentinel lymph node biopsy (SLNB)
  45. Regional lymphadenectomy
  46. Adjuvant therapy
  47. Immunotherapy
  48. Checkpoint inhibitors
  49. Pembrolizumab
  50. Treatment of Resectable Stage III Melanoma
  51. Treatment Options for Resectable Stage III Melanoma
  52. Excision
  53. Lymph node management
  54. Sentinel lymph node biopsy (SLNB)
  55. Regional lymphadenectomy
  56. Neoadjuvant therapy
  57. Immunotherapy
  58. Checkpoint inhibitors
  59. Pembrolizumab
  60. Ipilimumab and nivolumab
  61. Adjuvant therapy
  62. Immunotherapy
  63. Checkpoint inhibitors
  64. Nivolumab
  65. Pembrolizumab
  66. Ipilimumab
  67. Combination signal transduction inhibitors
  68. Dabrafenib plus trametinib
  69. Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma
  70. Treatment Options for Unresectable Stage III, Stage IV, and Recurrent Melanoma
  71. Immunotherapy
  72. Checkpoint inhibitors
  73. Anti–PD-1 and PD-L1 therapy
  74. Pembrolizumab
  75. Nivolumab
  76. Anti–cytotoxic T-lymphocyte antigen-4 (CTLA-4) therapy
  77. Ipilimumab
  78. High-dose IL-2
  79. Dual checkpoint inhibition
  80. CTLA-4 inhibitor plus PD-1 inhibitor
  81. LAG-3 inhibitor plus PD-1 inhibitor
  82. Signal transduction inhibitors
  83. BRAF inhibitors
  84. Vemurafenib
  85. Dabrafenib
  86. MEK inhibitors
  87. Trametinib
  88. Cobimetinib
  89. KIT inhibitors
  90. Combination therapy with signal transduction inhibitors
  91. BRAF inhibitor plus MEK inhibitors
  92. Dabrafenib plus trametinib
  93. Vemurafenib plus cobimetinib
  94. Encorafenib plus binimetinib
  95. Combination signal transduction inhibitor therapy plus PD-L1 inhibitor
  96. Cobimetinib and vemurafenib plus atezolizumab
  97. Tumor-infiltrating lymphocyte (TIL) therapy
  98. Lifileucel
  99. Intralesional therapy
  100. Talimogene laherparepvec (T-VEC)
  101. Palliative therapy
  102. Chemotherapy
  103. Radiation therapy
  104. Certain factors affect prognosis (chance of recovery) and treatment options.
  105. Melanoma can recur (come back) after it has been treated.
  106. Treatment Option Overview
  107. Key Points
  108. There are different types of treatment for people with melanoma.
  109. The following types of treatment are used:
  110. Surgery
  111. Chemotherapy
  112. Radiation therapy
  113. Immunotherapy
  114. Targeted therapy
  115. New types of treatment are being tested in clinical trials.
  116. Vaccine therapy
  117. Treatment for melanoma may cause side effects.
  118. Follow-up care may be needed.
  119. Treatment of Stage 0 (Melanoma in Situ)
  120. Treatment of Stage I Melanoma
  121. Treatment of Stage II Melanoma
  122. Treatment of Stage III Melanoma That Can Be Removed By Surgery
  123. Treatment of Stage III Melanoma That Cannot Be Removed By Surgery, Stage IV Melanoma, and Recurrent Melanoma

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.

Sources: biomarker tests · Biomarker Testing for Cancer Treatment

Targeted therapies used to treat melanoma include:

binimetinib

Sources: binimetinib

cobimetinib

Sources: cobimetinib

dabrafenib

Sources: dabrafenib

encorafenib

Sources: encorafenib

trametinib

Sources: trametinib

vemurafenib

Sources: vemurafenib

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Vaccine therapy

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Vaccine therapy is a cancer treatment that uses a substance or group of substances to stimulate the immune system to find the tumor and kill it. Vaccine therapy is being studied in the treatment of stage III melanoma that can be removed by surgery.

Sources: stage III melanoma

For patients · Treatment Option Overview

Treatment for melanoma may cause side effects.

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Stage 0 (Melanoma in Situ)

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage 0 is usually surgery to remove the area of abnormal cells and a small amount of normal tissue around it.

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage I Melanoma

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage I melanoma is usually surgery to remove the tumor and some of the normal tissue around it, with or without lymph node mapping and sentinel lymph node biopsy.

Sources: lymph node mapping · sentinel lymph node biopsy

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage II Melanoma

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage II melanoma may include:

surgery to remove the tumor and some of the normal tissue around it, with lymph node mapping and sentinel lymph node biopsy. If cancer is found in the sentinel lymph node, more lymph nodes may be removed.

Sources: lymph node mapping · sentinel lymph node biopsy · sentinel lymph node

surgery followed by immunotherapy with pembrolizumab if there is a high risk that the cancer will come back

Sources: immunotherapy · pembrolizumab

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Melanoma That Can Be Removed By Surgery

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage III melanoma that can be removed by surgery may include:

immunotherapy with pembrolizumab before surgery

Sources: immunotherapy · pembrolizumab

surgery to remove the tumor and some of the normal tissue around it, with or without skin grafting to cover the wound caused by surgery. Sometimes lymph node mapping and sentinel lymph node biopsy are done to check for cancer in the lymph nodes at the same time as the surgery to remove the tumor. If cancer is found in the sentinel lymph node, more lymph nodes may be removed.

Sources: skin grafting · lymph node mapping · sentinel lymph node biopsy · lymph nodes · sentinel lymph node

surgery followed by immunotherapy with nivolumab, pembrolizumab, or ipilimumab if there is a high risk that the cancer will come back

Sources: nivolumab · ipilimumab

surgery followed by targeted therapy with dabrafenib and trametinib if there is a high risk that the cancer will come back

Sources: targeted therapy · dabrafenib · trametinib

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Melanoma That Cannot Be Removed By Surgery, Stage IV Melanoma, and Recurrent Melanoma

Source: Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage III melanoma that cannot be removed by surgery, stage IV melanoma, and recurrent melanoma may include:

Sources: recurrent

immunotherapy with pembrolizumab, nivolumab, ipilimumab, interleukin-2 (IL-2), nivolumab and relatimab, or atezolizumab, given alone or in combination

Sources: immunotherapy · pembrolizumab · nivolumab · ipilimumab · interleukin-2 · nivolumab and relatimab · atezolizumab

targeted therapy with dabrafenib, trametinib, vemurafenib, cobimetinib, encorafenib, binimetinib, given alone or in combination

Sources: targeted therapy · dabrafenib · trametinib · vemurafenib · cobimetinib · encorafenib · binimetinib

oncolytic virus therapy (talimogene laherparepvec) injected into the tumor

Sources: oncolytic virus therapy · talimogene laherparepvec

palliative therapy to relieve symptoms and improve the quality of life:

Sources: palliative therapy · quality of life

palliative therapy to relieve symptoms and improve the quality of life:

chemotherapy

surgery to remove lymph nodes or tumors in the lung, digestive tract, bone, or brain

Sources: lymph nodes · lung · digestive tract

radiation therapy to the brain, spinal cord, or bone

Sources: radiation therapy · spinal cord

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

NCT00091572 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653 · COMPLETED · phase3

Melanoma, Metastases

ClinicalTrials.gov record

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168 · COMPLETED · phase3

High Risk Stage III Melanoma

ClinicalTrials.gov record

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

NCT01006980 · COMPLETED · phase3

Malignant Melanoma

ClinicalTrials.gov record

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

NCT01227889 · COMPLETED · phase3

Cancer

ClinicalTrials.gov record

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

NCT01266967 · COMPLETED · phase2

Melanoma and Brain Metastases

ClinicalTrials.gov record

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338 · ACTIVE NOT RECRUITING · phase3

Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7

ClinicalTrials.gov record

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

NCT01667419 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

NCT01704287 · COMPLETED · phase2

Malignant Melanoma

ClinicalTrials.gov record

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

NCT01721746 · COMPLETED · phase3

Unresectable or Metastatic Melanoma

ClinicalTrials.gov record

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

NCT01721772 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505 · COMPLETED · phase3

Unresectable or Metastatic Melanoma

ClinicalTrials.gov record

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

NCT01866319 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947 · COMPLETED · phase2

Melanoma and Brain Metastases

ClinicalTrials.gov record

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781 · ACTIVE NOT RECRUITING · phase3

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma

ClinicalTrials.gov record

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

NCT02320058 · COMPLETED · phase2

Melanoma

ClinicalTrials.gov record

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579 · COMPLETED · phase2

Metastatic Melanoma

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

NCT02362594 · ACTIVE NOT RECRUITING · phase3

Melanoma

ClinicalTrials.gov record

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)

NCT02434107 · COMPLETED · na

Melanoma

ClinicalTrials.gov record

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

NCT02908672 · COMPLETED · phase3

Melanoma

ClinicalTrials.gov record

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922 · ACTIVE NOT RECRUITING · phase2, phase3

Melanoma

ClinicalTrials.gov record

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836 · ACTIVE NOT RECRUITING · phase3

Melanoma

ClinicalTrials.gov record

Trial of Surgical Excision Margins in Thick Primary Melanoma - 2

NCT03638492 · COMPLETED · na

Melanoma, Surgery, Treatment Outcome

ClinicalTrials.gov record

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019 · ACTIVE NOT RECRUITING · phase2

Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma

ClinicalTrials.gov record

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251 · ACTIVE NOT RECRUITING · phase3

Melanoma

ClinicalTrials.gov record

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NCT04949113 · ACTIVE NOT RECRUITING · phase3

Malignant Melanoma Stage III

ClinicalTrials.gov record

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

NCT01213472 · COMPLETED · phase1

Melanoma

ClinicalTrials.gov record

Disease and treatment settings

Amtagvi: unresectable metastatic melanoma with BRAF V600, BRAF stated without a specific alteration

Disease and treatment setting

Adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

BRAFTOVI: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

• in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test.

Cotellic: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

1 INDICATIONS AND USAGE COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

Imlygic: unresectable recurrent melanoma after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

KEYTRUDA QLEX: unresectable metastatic melanoma

Disease and treatment setting

1.1 Melanoma KEYTRUDA QLEX ™ is indicated for the treatment of adult patients with unresectable or metastatic melanoma.

KEYTRUDA: unresectable metastatic melanoma

Disease and treatment setting

1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma.

Keytruda: unresectable metastatic melanoma with BRAF V600, BRAF stated without a specific alteration after prior therapy

Disease and treatment setting

Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

Mekinist: melanoma with BRAF V600E (adjuvant) after prior therapy

Disease and treatment setting

( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

Mekinist: melanoma with BRAF V600E (adjuvant) after prior therapy

Disease and treatment setting

1.2 Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an...

Mekinist: unresectable metastatic melanoma with BRAF stated without a specific alteration, BRAF V600E

Disease and treatment setting

1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by...

Mekinist: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

In combination with dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test

Mekinist: unresectable metastatic melanoma with BRAF V600E, BRAF stated without a specific alteration

Disease and treatment setting

1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKINIST ® is indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with...

MEKTOVI: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K...

Melanoma

Disease and treatment setting

Melanoma

Opdivo: unresectable metastatic melanoma with BRAF stated without a specific alteration, BRAF V600 after prior therapy

Disease and treatment setting

1) In combination with ipilimumab for unresectable or metastatic melanoma to remove the restriction for treatment of only patients with BRAF wild-type melanoma; 2) As a single agent for BRAF V600 mutation positive unresectable or...

Opdivo: unresectable metastatic melanoma with BRAF V600

Disease and treatment setting

In combination with ipilimumab for BRAF V600 wild-type unresectable or metastatic melanoma

Opdivo: unresectable metastatic melanoma with BRAF V600, BRAF stated without a specific alteration after prior therapy

Disease and treatment setting

Unresectable or metastatic melanoma and progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor

Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

Disease and treatment setting

Pathologic Stage IIIA Cutaneous Melanoma AJCC v8

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

Disease and treatment setting

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Disease and treatment setting

Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Disease and treatment setting

Pathologic Stage IIID Cutaneous Melanoma AJCC v8

PROLEUKIN: metastatic melanoma

Disease and treatment setting

1.2 Metastatic Melanoma Proleukin is indicated for the treatment of adults with metastatic melanoma.

Stage 0 Melanoma

Disease and treatment setting

Treatment of Stage 0 Melanoma

Stage I Melanoma

Disease and treatment setting

Treatment of Stage I Melanoma

Stage IA Melanoma

Disease and treatment setting

Treatment of Stage IA Melanoma

Stage IB Melanoma

Disease and treatment setting

Treatment of Stage IB Melanoma

Stage II Melanoma

Disease and treatment setting

Treatment of Stage II Melanoma

Stage III Melanoma

Disease and treatment setting

Treatment of Resectable Stage III Melanoma

Stage III Melanoma

Disease and treatment setting

Treatment of Stage III Melanoma That Can Be Removed By Surgery

Stage III recurrent Melanoma

Disease and treatment setting

Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease

Stage III recurrent Melanoma

Disease and treatment setting

Treatment of Stage III Melanoma That Cannot Be Removed By Surgery, Stage IV Melanoma, and Recurrent Melanoma

Tafinlar: melanoma with BRAF V600E (adjuvant) after prior therapy

Disease and treatment setting

1.3 Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an...

Tafinlar: melanoma with BRAF V600E (adjuvant) after prior therapy

Disease and treatment setting

( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

Tafinlar: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

In combination with trametinib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test

Tecentriq Hybreza: unresectable metastatic melanoma with BRAF V600

Disease and treatment setting

1.4 Melanoma TECENTRIQ HYBREZA, in combination with cobimetinib and vemurafenib, is indicated for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test...

TECENTRIQ: unresectable metastatic melanoma with BRAF V600

Disease and treatment setting

1.4 Melanoma TECENTRIQ, in combination with cobimetinib and vemurafenib, is indicated for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma [see Dosage and Administration (2.1) ] .

Tudriqev: unresectable advanced melanoma

Disease and treatment setting

In combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen

YERVOY: melanoma (adjuvant)

Disease and treatment setting

• Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.

ZELBORAF: unresectable metastatic melanoma with BRAF V600E

Disease and treatment setting

1 INDICATIONS AND USAGE ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Drug labels

AMTAGVI

Label date 2025-10-14

AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a...

DailyMed label

Cotellic

Label date 2026-07-29

COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the...

DailyMed label

Imlygic

Label date 2025-04-04

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use :...

DailyMed label

Mekinist

Label date 2026-05-07

MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. (...

DailyMed label

Tafinlar

Label date 2026-05-20

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in...

DailyMed label

Tudriqev

Label date 2026-09-01

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based...

DailyMed label

YERVOY

Label date 2026-08-20

YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in...

DailyMed label

ZELBORAF

Label date 2026-08-28

ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) ZELBORAF ® is indicated for the treatment of...

DailyMed label